LivingGLP1
Study S001357

A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease

Included trial: extracted dataClinicalTrials.gov recordStudy Protocol and Statistical Analysis Plan (PDF)

Registration

Registration
NCT02953665
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2
Masking
QUADRUPLE
Status
COMPLETED
Enrollment
63
Start
2017-04-03
Primary completion
2022-08-03
Lead sponsor
Cedars-Sinai Medical Center
Conditions
Parkinson Disease
Interventions
DRUG:Liraglutide; DRUG:Placebo
Results posted
TRUE
Individual participant data sharing
NO

Registered primary outcomes

  • Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "OFF" Time From Baseline to the End of Double-Blind Maintenance Period [From Baseline (Week 0) to end of Maintenance Period (up to 54 weeks)]
  • Change in the Non-Motor Symptoms Scale (NMSS) Total Score From Baseline to the End of the Double-Blind Maintenance Period [From Baseline (Week 0) to the End of Maintenance Period (up to Week 54)]
  • Change in the Mattis Dementia Rating Scale (DRS-2) From Baseline to the End of Double-Blind Maintenance Period [From Baseline (Week 0) to the end of Maintenance Period (up to 54 weeks)]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0008417The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
Zhang L, Journal of Parkinson's disease
2020Other trialPMID 31958096DOIcites ClinicalTrials.gov:NCT02953665; registry reference DERIVED:31958096
R0028596Glucagon-like Peptides (GLP-1) Perspectives in Synucleinopathies Treatment.
Foltynie T, Movement disorders clinical practice
2018Randomized trialPMID 30800701DOIcites ClinicalTrials.gov:NCT02953665